Medibank Private Limited's (ASX:MPL) dividend will be increasing from last year's payment of the same period to A$0.102 on 9th of October. This takes the annual payment to 3.5% of the current stock price, which is about average for the industry. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Medibank Private's Payment Could Potentially Have Solid Earnings Coverage We aren't too impressed by dividend yields unless they can be sustained over time. Prior to this announcement, the company was paying out 99% of what it was earning. It will be difficult to sustain this level of payout so we wouldn't be confident about this continuing. Over the next year, EPS is forecast to expand by 42.7%. Under the assumption that the dividend will continue along recent trends, we think the payout ratio could be 75% which would be quite comfortable going to take the dividend forward.ASX:MPL Historic Dividend August 30th 2025 View our latest analysis for Medibank Private Medibank Private Has A Solid Track Record The company has a sustained record of paying dividends with very little fluctuation. The annual payment during the last 10 years was A$0.053 in 2015, and the most recent fiscal year payment was A$0.18. This means that it has been growing its distributions at 13% per annum over that time. We can see that payments have shown some very nice upward momentum without faltering, which provides some reassurance that future payments will also be reliable. There Isn't Much Room To Grow The Dividend The company's investors will be pleased to have been receiving dividend income for some time. It's encouraging to see that Medibank Private has been growing its earnings per share at 9.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by the amount of earnings being paid out to shareholders. The Dividend Could Prove To Be Unreliable Overall, we always like to see the dividend being raised, but we don't think Medibank Private will make a great income stock. Although they have been consistent in the past, we think the payments are a little high to be sustained. We would be a touch cautious of relying on this stock primarily for the dividend income. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. However, there are other things to consider for investors when analysing stock performance. For instance, we've picked out 1 warning sign for Medibank Private that investors should take into consideration. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments
Medibank Private (ASX:MPL) Is Paying Out A Larger Dividend Than Last Year
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...